𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies

✍ Scribed by Thomas E. Witzig; Scott H. Kaufmann

Book ID
107531963
Publisher
Springer
Year
2006
Tongue
English
Weight
675 KB
Volume
7
Category
Article
ISSN
1527-2729

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mammalian target of rapamycin inhibition
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
✍ Corey Cutler; Joseph H. Antin πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 32 KB

P anwalkar and colleagues present a very complete overview on the evolving role of mammalian target of rapamycin (mTOR) inhibitors in the treatment of both hematologic and nonhematologic malignancies. We wish to clarify selected statements made by the authors. We would like to point out that all mT

Mammalian target of rapamycin inhibition
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
✍ Amit Panwalkar; Srdan Verstovsek; Francis J. Giles πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 588 KB

## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3‐kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal‐transduction pathways, is involved in the coupling of g

Curcumin inhibits the mammalian target o
Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells
✍ Christopher S. Beevers; Fengjun Li; Lei Liu; Shile Huang πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 546 KB

## Abstract Curcumin (diferuloylmethane), a polyphenol natural product of the plant __Curcuma longa__, is undergoing early clinical trials as a novel anticancer agent. However, the anticancer mechanism of curcumin remains to be elucidated. Here we show that curcumin inhibited growth of rhabdomyosar